Effectiveness of 2024/25 KP.2 vaccine against outpatient COVID-19 in Canada
Separovic, L.; Sabaiduc, S.; Zhan, Y.; Kaweski, S. E.; Carazo, S.; Olsha, R.; Mather, R. G.; Lacroix, C.; Hasso, M.; Levade, I.; Meunier, I.; Jassem, A. N.; Dover, K.; Gao, R.; Bastien, N.; Skowronski, D. M.
Show abstract
Between November 2024 and April 2025, the Canadian Sentinel Practitioner Surveillance Network assessed KP.2 vaccine effectiveness against outpatient COVID-19 by test-negative design. Vaccination protected best during the first two months, reducing risk by two-thirds among vaccinated versus unvaccinated individuals, declining by 3-4 months, and reducing the risk overall by half.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada 96%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 96%
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 95%
Similar papers in this journal
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 94%
- Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine 94%
- Strength and durability of antibody responses to BNT162b2 and CoronaVac 93%
Similar papers in this journal
- Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network 95%
- Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged ≥12 Years with Reported Contact with COVID-19 Cases, February – September 2021 95%
- mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020-December 2021 93%
Similar papers in this journal
- Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada 97%
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 95%
- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February – May 2021 94%
Similar papers in this journal
- Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis 92%
- Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death 92%
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.